Animal models of pulmonary hypertension: Getting to the heart of the problem

Joshua P. Dignam,Tara E. Scott,Barbara K. Kemp‐Harper,Adrian J. Hobbs
DOI: https://doi.org/10.1111/bph.15444
IF: 7.3
2021-05-12
British Journal of Pharmacology
Abstract:Despite recent therapeutic advances, pulmonary hypertension (PH) remains a fatal disease due to the development of right ventricular (RV) failure. At present, no RV‐targeted therapies are available, and RV function is not widely considered in the preclinical assessment of new therapeutics. Several small animal models are used in the study of PH, including the classic models of exposure to either hypoxia or monocrotaline, newer combinational and genetic models, and pulmonary artery banding, a surgical model of pure RV pressure overload. These models recapitulate selected features of the structural remodelling and functional decline seen in patients and have provided valuable insight into the pathophysiology of RV failure. However, significant reversal of remodelling and improvement in RV function remains a therapeutic obstacle. Emerging animal models will provide a deeper understanding of the mechanisms governing the transition from adaptive remodelling to a failing RV, aiding the hunt for druggable molecular targets.
pharmacology & pharmacy
What problem does this paper attempt to address?